New Brunswick, N.J., December 2, 2025 – Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will share new discoveries from their basic science and clinical research programs to advance the understanding of blood cancers, such as lymphoma, leukemia and multiple myeloma, as well as classical hematology disorders at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida (and online). Rutgers Cancer Institute, New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, will be featured prominently at this year’s meeting with a total of 93 accepted peer-reviewed scientific abstracts, including 32 oral presentations, 60 poster presentations and 1 satellite symposium.
“ASH is a vital platform to present critical breakthroughs that are transforming the science and clinical care in blood diseases, and our prominent involvement reflects our commitment to deliver meaningful progress for patients and the exceptional scientific leadership of our research teams,” said Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services and Chief Physician Officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center and System Director of Medical Oncology, RWJBarnabas Health . “Our faculty’s remarkable work highlights the innovation and ground-breaking discoveries that define Rutgers Cancer Institute and RWJBarnabas Health. With the Jack & Sheryl Morris Cancer Center, New Jersey’s only freestanding cancer hospital, now open, we are entering a new era of care and research that brings world-class inpatient and outpatient treatment together with leading science to accelerate discoveries and improve outcomes for patients and families across our state and beyond.”
Key scientific contributions from Rutgers Cancer Institute and RWJBarnabas Health at ASH 2025:
-
Abs25-2080: Data from a comparative study evaluated PET-adaptive BEACOPP- versus ABVD-based therapies for advanced-stage classic Hodgkin lymphoma (cHL). Researchers compared outcomes from escBEACOPP and ABVD across 2,381 adults using data from four clinical trials and adjusting for baseline risk with the A-HIPI prognostic score. escBEACOPP was associated with significantly better progression-free survival, and multistate modeling showed a lower likelihood of treatment failure both before and after achieving one-year remission. These findings suggest that escBEACOPP offers stronger disease control in PET-adaptive strategies, while the A-HIPI score remains a powerful predictor of risk throughout the treatment course.
-
Abs25-2547: A study assessed the performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the SWOG S1826 randomized trial of nivolumab-AVD versus brentuximab-AVD. Using locked model parameters and Cox regression analyses, the A-HIPI demonstrated strong prognostic capability, with clear separation of 3-year progression-free survival across predicted risk quartiles and superior discrimination compared with the historic IPS-7. The A-HIPI performed similarly across treatment arms and remained superior in multivariable modeling, confirming it as a more precise, treatment-agnostic tool for risk stratification in newly diagnosed advanced-stage classical Hodgkin lymphoma.
-
Abs25-12859: Researchers conducted a large multicenter real-world analysis evaluating the use and safety of peripheral intravenous catheters (PIV) versus central venous catheters (CVC) for frontline anthracycline-based chemotherapy in lymphoma. Among 1,414 patients treated with CHOP- or ABVD-based regimens across eight U.S. centers, extravasation was rare in both groups, with only one documented case in the CVC cohort and two suspected cases in the PIV cohort. No significant differences were observed in induration, phlebitis/cellulitis, venous thromboembolism, or erythema. While PIV use was associated with higher rates of local pain/tenderness and infiltration, events were uncommon and self-limited. Overall, PIV access was found to be safe with a low rate of serious complications over more than 9,000 treatments, supporting its selective use despite the common default to CVC placement.
-
Abs25-8890: A first report from Part 1 of the Phase 3 OLYMPIA-3 study examined odronextamab plus chemotherapy in previously untreated diffuse large B-cell lymphoma (DLBCL). The Part 1A analysis assessed two dose levels in 22 patients, with primary endpoints focused on dose-limiting toxicities and treatment-emergent adverse events. No dose-limiting toxicities occurred, and the safety profile was manageable, with neutropenia, cytokine release syndrome, anemia, and infections as the most common adverse events. All patients experienced Grade ≥3 TEAEs, though CRS events were limited to Grade 1–2 and no tumor lysis syndrome was observed. Preliminary efficacy was encouraging, with ORR of 77.8% and CR rate of 66.7% at DL1 and both ORR and CR of 100% at DL2, with median duration of response not reached. These early results suggest rituximab may not be required to achieve depth of response in this frontline setting.
-
Abs25-7103: A retrospective real-world evidence study investigated racial and ethnic inequities in access to guideline-preferred first-line therapies for chronic lymphocytic leukemia (CLL). Using data from 4,452 patients in the Flatiron Health Research Database linked with neighborhood-level social determinants of health, researchers found that Black and Hispanic patients were more likely to live in high-deprivation areas and were less likely than White patients to receive NCCN-preferred novel therapies. Structural factors—including residential segregation, socioeconomic status, limited internet access, vehicle ownership, and health insurance—were associated with lower use of preferred first-line treatments. Findings underscore the role of neighborhood-level barriers in limiting equitable access to novel therapies.
The full list of presentations at this year’s ASH Annual Meeting and Exposition follows:
Oral Presentations
|
Abstract and Session No. |
Title |
Presentation Date/Time |
|
Abstract 2080 |
PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course |
Saturday, December 6, 2025: 10:00 AM EST |
|
Abstract 8890 |
Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study |
Saturday, December 6, 2025: 10:30 AM EST |
|
Abstract 8861 |
Inadequate social support and household material hardship among children with pediatric acute lymphoblastic leukemia: A report from the Children’s oncology group Trial AALL1731 |
Saturday, December 6, 2025: 10:45 AM EST |
|
Abstract 10420 |
3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma |
Saturday, December 6, 2025: 12:00 PM EST |
|
Abstract 2547 |
Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) |
Saturday, December 6, 2025: 12:45 PM EST |
|
Abstract 1877 (Session 623) |
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study |
Saturday, December 6, 2025: 2:45 PM EST |
|
Abstract 7883 |
Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium |
Saturday, December 6, 2025: 4:15 PM EST |
|
Abstract 8300 |
Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826 |
Saturday, December 6, 2025: 4:30 PM EST |
|
Abstract 11525 |
Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status |
Saturday, December 6, 2025: 4:45 PM EST |
|
Abstract 2855 |
Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis. |
Saturday, December 6, 2025: 5:00 PM EST |
|
Abstract 2876 |
Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms |
Saturday, December 6, 2025: 5:00 PM EST |
|
Abstract 7426 |
Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study |
Saturday, December 6, 2025: 5:15 PM EST |
|
Abstract 12859 |
The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA) |
Sunday, December 7, 2025: 9:45 AM EST |
|
Abstract 2328 |
Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy |
Sunday, December 7, 2025: 10:00 AM EST |
|
Abstract 11072 |
Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL) |
Sunday, December 7, 2025: 12:45 PM EST |
|
Abstract 2553 |
Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial |
Sunday, December 7, 2025: 4:30 PM EST |
|
Abstract 4477 |
Cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment: A report from the DFCI ALL 16-001 Trial |
Sunday, December 7, 2025: 4:45 PM EST |
|
Abstract 8255 |
Outcome of children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia: Results of DFCI ALL consortium protocol 16-001 |
Sunday, December 7, 2025: 4:45 PM EST |
|
Abstract 14842 |
Loss of serine threonine protein kinase 25 (STK25) in the bone marrow niche attenuates g/CSF- and TLR7-induced emergency myelopoiesis and mobilization into the periphery |
Sunday, December 7, 2025: 5:00 PM EST |
|
Abstract 7068 |
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study |
Sunday, December 7, 2025: 5:30 PM EST |
|
Abstract 2036 |
Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia |
Monday, December 8, 2025: 10:30 AM EST |
|
Abstract 7179 |
Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL |
Monday, December 8, 2025: 10:30 AM EST |
|
Abstract 2921 |
Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis |
Monday, December 8, 2025: 11:00 AM EST |
|
Abstract 3889 |
Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007 |
Monday, December 8, 2025: 11:15 AM EST |
|
Abstract 4341 |
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma |
Monday, December 8, 2025: 11:15 AM EST |
|
Abstract 3910 |
Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007 |
Monday, December 8, 2025: 11:45 AM EST |
|
Abstract 2255 |
Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants |
Monday, December 8, 2025: 2:45 PM EST |
|
Abstract 8435 |
Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study |
Monday, December 8, 2025: 3:30 PM EST |
|
Abstract 3951 |
Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium |
Monday, December 8, 2025: 4:00 PM EST |
|
Abstract 2025 |
Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial |
Monday, December 8, 2025: 4:30 PM EST |
|
Abstract 9193 |
Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL) |
Monday, December 8, 2025: 5:00 PM EST |
|
Abstract 10590 |
Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis |
Monday, December 8, 2025: 3:45 PM EST |
Poster Presentations
|
Abstract and Session No. |
Title |
Presentation Date/Time |
|
Abstract 1945 |
Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 2368 |
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 2819 |
Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 4233 |
Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 7103 |
Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study |
Saturday, December 6, 5:30 PM EST |
|
Abstract 7390 |
Clinical burden and predictors of cytokine release syndrome in CAR-T cell therapy for hematologic malignancies: Insights from a national cohort |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 7483 |
Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 7870 |
An analysis of sickle cell disease content on tiktok |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 9064 |
External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 9154 |
The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 9859 |
Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children’s oncology group |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 9990 |
Genomic and transcriptomic landscape of extranodal marginal zone lymphoma |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 10077 |
A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 10798 |
Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 12476 |
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 12591 |
Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 12637 |
Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 12645 |
Bleed-versus-clot paradox under immune-checkpoint inhibition: A decade-long US faers analysis reveals divergent class-specific hemostatic phenotypes |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 13300 |
Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 14265 |
A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 15032 |
Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 15587 |
Signal-rich and signal-poor: Divergent detection of early bacterial sepsis and latent viral complications after hematopoietic stem cell transplantation in the FDA adverse event reporting system |
Saturday, December 6, 2025: 5:30 PM EST |
|
Abstract 1471 |
A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 2100 |
Integrated machine learning, cosmic signatures, and AI-driven genomic profiling of highly heterogeneous blast crisis CML at single patient level resolution: Implication as a versatile risk stratification and precision oncology approach for refractory and relapsed cancers in AI/ML era |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 2129 |
Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 2239 |
Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 7156 |
Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts) |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 7379 |
Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 7401 |
Aggressive lymphomas that are treated early have worse outcomes: Counterintuitive results from a national database study. |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 7840 |
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world? |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 7936 |
Platelet proteomic signatures reveal neurodegenerative and mitochondrial pathways associated with pain phenotypes in sickle cell disease |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 7940 |
Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 8462 |
Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND) |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 8658 |
Identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective graft-versus-leukemia effect |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 9029 |
First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 9628 |
Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 9969 |
Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 11387 |
Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 12035 |
DNMT3A-driven clonal hematopoiesis permits colitis-associated tumorigenesis by promoting innate immune tolerance |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 13102 |
Age at diagnosis shapes stage and survival in diffuse large B-cell lymphoma: A 22-year, population-based study of 94,598 SEER patients |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 13467 |
Risk factors and mortality associated with venous thromboembolism in elderly patients with non-Hodgkin lymphoma |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 13531 |
Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 13895 |
Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 14141 |
Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 15000 |
National trends and demographic disparities in perinatal non-traumatic intracranial hemorrhage mortality in the United States, 1999–2024 |
Sunday, December 7, 2025: 6:00 PM EST |
|
Abstract 2026 |
Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 2148 |
Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 4117 |
Association of low annexin A2 levels with venous thromboembolism in sickle cell anemia: A potential biomarker |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 4208 |
Mitochondrial suppression in Acute Myeloid Leukemia and Myelodysplastic Syndromes: A two-cohort transcriptomic analysis using GEO |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 4620 |
Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 4655 |
Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 8049 |
Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 8348 |
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 9115 |
Time-stratified risk of second primary solid malignancies among follicular lymphoma survivors in the United States |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 11263 |
Association of opioid use disorder and thrombotic events in hospitalized patients: A national inpatient database study |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 11518 |
Clinical outcomes associated with opioid use disorder in hospitalized patients with venous thromboembolism |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 12048 |
Comparison of paired bone marrow and peripheral blood measurable residual disease in pediatric acute lymphoblastic leukemia by next-generation sequencing: A report from the dana farber ALL consortium protocol 16-001. |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 12530 |
Associations between serum asparaginase activity and asparaginase-associated toxicities in pediatric ALL patients receiving calaspargase: A report from the DFCI ALL consortium |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 14277 |
Impact of venous thromboembolism on clinical outcomes in patients with brain cancer: A national inpatient sample analysis from 2018-2020 |
Monday, December 8, 2025: 6:00 PM EST |
|
Abstract 14731 |
Immune checkpoint inhibitor–associated cytopenias: A decade of real-world signal detection from faers (2014–2025) |
Monday, December 8, 2025: 6:00 PM EST |
Program: Friday Satellite Symposia
|
Abstract and Session No. |
Title |
Presentation Date/Time |
|
N/A |
Friday, December 5, 2025: 7:00 PM-10:00 PM EST |
About RWJBarnabas Health
RWJBarnabas Health is New Jersey’s largest and most comprehensive academic health system, caring for more than five million people annually. Nationally renowned for quality and safety, the system includes 14 hospitals and 9,000 affiliated physicians integrated to provide care at more than 700 patient care locations.
RWJBarnabas Health partners with its communities to build and sustain a healthier New Jersey. It provides patient-centered care in a compassionate manner and is the state’s largest safety-net provider and leader in addressing the social determinants of health. RWJBarnabas Health provides food to the hungry, housing for the homeless and economic opportunities to those most vulnerable.
RWJBarnabas Health’s commitment to enhancing access to care includes a transformative partnership with Rutgers University, including the Rutgers Cancer Institute — the state's only NCI-designated Comprehensive Cancer Center, and Rutgers Robert Wood Johnson Medical School.
RWJBarnabas Health is among New Jersey’s largest private employers, with more than 44,000 employees, contributing more than $7 billion to the state economy every year. For more information, visit www.RWJBH.org
About Rutgers Cancer Institute
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, provides patients access to the most advanced treatment options including clinical trials close to home at our facilities throughout the state. Our groundbreaking cancer research is the engine that drives access to the most advanced cancer treatments, where our discoveries become your care. This has been enhanced with the opening of the state’s first and only freestanding cancer hospital, the Jack & Sheryl Morris Cancer Center. Visit: www.cinj.org.
Media Contact:
Krista Didzbalis
Corporate Communications Specialist, Strategic Communications, RWJBarnabas Health
732.507.8307
krista.didzbalis2@rwjbh.org